Hims & Hers Health (NYSE:HIMS) Price Target Cut to $32.00 by Analysts at Needham & Company LLC

Hims & Hers Health (NYSE:HIMS) had its price target lowered by Needham & Company LLC from $42.00 to $32.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC‘s target price would suggest a potential upside of 39.76% from the company’s current price.

A number of other equities research analysts have also recently commented on HIMS. Truist Financial increased their target price on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a report on Monday, August 24th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Morgan Stanley lifted their price target on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Finally, Citigroup cut their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $31.77.

Hims & Hers Health Trading Down 11.9%

Shares of HIMS stock opened at $22.90 on Tuesday. The stock has a market cap of $5.34 billion, a P/E ratio of -36.34 and a beta of 2.53. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $42.70. The business has a fifty day simple moving average of $28.31 and a 200-day simple moving average of $26.91.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. Hims & Hers Health’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 earnings per share. On average, analysts forecast that Hims & Hers Health will post -0.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 3,462 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $27.60, for a total transaction of $95,551.20. Following the sale, the insider directly owned 293,886 shares in the company, valued at approximately $8,111,253.60. This trade represents a 1.16% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total value of $398,226.53. Following the transaction, the chief operating officer directly owned 456,660 shares in the company, valued at $12,964,577.40. This trade represents a 2.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 133,905 shares of company stock valued at $3,826,977. 11.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Large investors have recently bought and sold shares of the company. Western Wealth Management LLC raised its stake in shares of Hims & Hers Health by 6.8% during the third quarter. Western Wealth Management LLC now owns 9,072 shares of the company’s stock valued at $270,000 after purchasing an additional 580 shares during the period. Harbour Investments Inc. boosted its stake in shares of Hims & Hers Health by 111.6% in the third quarter. Harbour Investments Inc. now owns 28,373 shares of the company’s stock valued at $845,000 after purchasing an additional 14,963 shares during the period. Virtus Advisers LLC boosted its stake in shares of Hims & Hers Health by 25.1% in the third quarter. Virtus Advisers LLC now owns 8,897 shares of the company’s stock valued at $265,000 after purchasing an additional 1,785 shares during the period. New York Life Investment Management LLC acquired a new stake in Hims & Hers Health during the 3rd quarter valued at $865,000. Finally, AlphaCore Capital LLC acquired a new stake in Hims & Hers Health during the 3rd quarter valued at $355,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Third-quarter revenue rose about 49% year over year to $890.4 million, while the subscriber base remained substantial at 2.8 million. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Neuroscientist and popular health educator Andrew Huberman joined the board. His profile could support the company’s brand, though the appointment’s financial impact is not yet clear. Article: Dr. Andrew Huberman Joins Hims & Hers Board of Directors
• Negative Sentiment: Adjusted earnings were $0.03 per share, below estimates of roughly $0.06–$0.07, and revenue of $890.4 million narrowly missed the $893.1 million consensus. The company also narrowed its 2026 revenue outlook, with climbing costs and contracting margins weighing on its profit forecast. These results have extended the stock’s recent weakness. Article: Hims & Hers narrows 2026 revenue forecast as margins contract
• Negative Sentiment: Subscriber numbers reached 2.8 million but fell by 100,000 on a net basis, raising questions about customer growth alongside the weaker outlook. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors

About Hims & Hers Health

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.